2015 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/11/15XBiotech Announces Agreement With the NCIC Clinical Trials Group to Collaborate on Phase II Study in Non-Small Cell Lung Cancer (NSCLC)Printer Friendly Version
12/07/15XBiotech Announces Positive Results in European Phase III Study for Its Breakthrough Therapy for Colorectal CancerPrinter Friendly Version
11/23/15XBiotech Provides Update on Phase III Oncology Study in EuropePrinter Friendly Version
11/20/15XBiotech Added to the MSCI US Small Cap 1750 and the MSCI Investable Market 2500 IndexesPrinter Friendly Version
11/12/15XBiotech Provides Third Quarter 2015 Corporate and Clinical UpdatePrinter Friendly Version
11/11/15XBiotech Identifies Positive Donors for Anti-Clostridium difficile Therapeutic Antibody Only Two Weeks After Initial ScreeningPrinter Friendly Version
11/09/15XBiotech Announces Positive Results for Its Anti-Ebola Therapeutic Candidates Following Evaluation by USAMRIIDPrinter Friendly Version
11/05/15XBiotech to Provide Third Quarter Business UpdatePrinter Friendly Version
10/26/15XBiotech Initiates Program to Develop Antibody Against Clostridium DifficilePrinter Friendly Version
10/21/15XBiotech Presents Findings at Investigator Conference for Staphylococcus Aureus ProgramPrinter Friendly Version
10/19/15XBiotech Strengthens Intellectual Property Portfolio for Its True Human(TM) Antibody TechnologyPrinter Friendly Version
10/02/15XBiotech Announces Publication of Clinical Results Supporting the Potential of Its True Human(TM) Antibody as a Cardiovascular TherapyPrinter Friendly Version
10/01/15XBiotech Receives FDA Fast Track Designation for Its Novel True Human(TM) Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus AureusPrinter Friendly Version
09/01/15XBiotech Advances Phase 1/2 Clinical Study of Novel True Human(TM) Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus AureusPrinter Friendly Version
08/17/15XBiotech Completes Enrollment for Xilonix(TM) Phase III Registration Study in EuropePrinter Friendly Version
08/07/15XBiotech Announces Expansion of Global Phase 3 Registration Study in Europe using Xilonix(TM) for Treatment of Metastatic Colorectal CancerPrinter Friendly Version
07/28/15XBiotech Provides Second Quarter 2015 Corporate and Clinical UpdatePrinter Friendly Version
07/15/15XBiotech to Provide Second Quarter Business UpdatePrinter Friendly Version
07/07/15XBiotech Announces Publication of Clinical Results Supporting Its True Human(TM) Antibody Therapy for Type 2 Diabetes MellitusPrinter Friendly Version
07/06/15XBiotech Treats First Patient in Phase 1/2 Clinical Study of Novel True Human(TM) Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus aureusPrinter Friendly Version
07/01/15XBiotech Conducts Investigators Meeting to Update the Status of Its Phase III Registration Study Underway in EuropePrinter Friendly Version
06/24/15XBiotech Added to Russell 2000 IndexPrinter Friendly Version
06/15/15CORRECTING and REPLACING -- XBiotech Announces Publication of Phase 2 Clinical Results for Its True Human(TM) Antibody MABp1 for Treating Acne VulgarisPrinter Friendly Version
06/15/15XBiotech Announces Publication of Phase 2 Clinical Results for Its True Human(TM) Antibody MABp1 for Treating Acne VulgarisPrinter Friendly Version
06/08/15XBiotech Appoints Kelly R. Thornburg as Senior Vice President of OperationsPrinter Friendly Version
05/28/15XBiotech Launching Phase 1/2 Clinical Study of Novel True Human(TM) Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus AureusPrinter Friendly Version
05/26/15XBiotech Successfully Clones First Anti-Ebola Therapeutic Antibody Product CandidatePrinter Friendly Version
05/18/15XBiotech Secures Approval From Data Safety Monitoring Board to Continue Phase 3 Registration Study in Europe for Its Novel Cancer ImmunotherapyPrinter Friendly Version
04/29/15XBiotech Enrolls First Patient Under Revised Protocol for U.S. Phase 3 Registration Study Using Xilonix(TM) for Treatment of Metastatic Colorectal CancerPrinter Friendly Version
04/01/15XBiotech Announces Publication of Positive Clinical Results for Xilonix™ in Non-Small Cell Lung CancerPrinter Friendly Version
03/12/15XBiotech Launches Website and Call Center to Inform Cancer Patients about New Xilonix™ Therapy and Phase III Clinical StudyPrinter Friendly Version
03/04/15XBiotech Announces Phase II Psoriasis Study Results in JAMA DermatologyPrinter Friendly Version
02/24/15XBiotech Plans to Conduct Initial Public Offering of its Common StockPrinter Friendly Version